Imatinib mesylate (Gleevec) induced remission in Philadelphia chromosome-negative BCR-ABL negative atypical chronic myelogenous leukemia (CML).

被引：0
|
作者：
Seftel, MD
Horsman, DE
Berry, B
Parslow, M
Pewarchuk, WJ
Nantel, SH
机构：
[1] Vancouver Gen Hosp, Leukemia BMT Program British Columbia, Vancouver, BC, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[3] Capital Hlth Reg, Dept Pathol, Victoria, BC, Canada
[4] Cowichan Community Canc Ctr, Cowichan, BC, Canada
[5] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4856
引用
收藏
页码：326B / 327B
页数：2
相关论文
共 50 条
  • [21] Y-CHROMOSOME STRUCTURAL REARRANGEMENT IN PHILADELPHIA CHROMOSOME-NEGATIVE CHRONIC MYELOGENOUS LEUKEMIA
    VERHEST, A
    LUSTMAN, F
    NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (01): : 53 - 54
  • [22] RAS MUTATIONS ARE RARE EVENTS IN PHILADELPHIA CHROMOSOME-NEGATIVE/BCR GENE REARRANGEMENT-NEGATIVE CHRONIC MYELOGENOUS LEUKEMIA, BUT ARE PREVALENT IN CHRONIC MYELOMONOCYTIC LEUKEMIA
    HIRSCHGINSBERG, C
    LEMAISTRE, AC
    KANTARJIAN, H
    TALPAZ, M
    CORK, A
    FREIREICH, EJ
    TRUJILLO, JM
    LEE, MS
    STASS, SA
    BLOOD, 1990, 76 (06) : 1214 - 1219
  • [23] Insertion of the ABL gene into the BCR region in a Philadelphia chromosome-negative chronic myeloid leukaemia
    Valle, L.
    de Gabriel, V. Fernandez
    Carralero, M. C.
    Perez-Pons, C.
    Benitez, J.
    Urioste, M.
    CHROMOSOME RESEARCH, 2005, 13 : 191 - 191
  • [24] REARRANGEMENT OF THE BCR GENE IN PHILADELPHIA CHROMOSOME-NEGATIVE CHRONIC MYELOID-LEUKEMIA
    GANESAN, TS
    RASSOOL, F
    GUO, AP
    THNG, KH
    DOWDING, C
    HIBBIN, JA
    YOUNG, BD
    WHITE, H
    KUMARAN, TO
    GALTON, DAG
    GOLDMAN, JM
    BLOOD, 1986, 68 (04) : 957 - 960
  • [25] ESSENTIAL THROMBOCYTHEMIA WITH THE PHILADELPHIA-CHROMOSOME AND BCR-ABL GENE REARRANGEMENT - AN ENTITY DISTINCT FROM CHRONIC MYELOID-LEUKEMIA AND PHILADELPHIA CHROMOSOME-NEGATIVE ESSENTIAL THROMBOCYTHEMIA
    LEBRUN, DP
    PINKERTON, PH
    SHERIDAN, BL
    CHENLAI, J
    DUBE, ID
    POLDRE, PA
    CANCER GENETICS AND CYTOGENETICS, 1991, 54 (01) : 21 - 25
  • [26] Fluorescent in situ hybridization analysis of Philadelphia chromosome-negative chronic myeloid leukemia with the bcr/abl fusion gene
    Monma, F
    Nishii, K
    Yamamori, S
    Hosokai, N
    Nakazaki, T
    Lorenzo, F
    Usui, E
    Sakakura, M
    Miyashita, H
    Fujieda, A
    Ohishi, K
    Katayama, N
    Shiku, H
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 80 (02) : 155 - 158
  • [27] Results of imatinib mesylate (STI571), a bcr-abl tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (Ph plus CML BP).
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Albitar, M
    Rios, MB
    Shan, J
    Faderl, S
    Garcia-Manero, G
    Issa, JP
    Thomas, D
    Capdeville, R
    Talpaz, M
    BLOOD, 2001, 98 (11) : 260B - 260B
  • [28] Fluorescent In Situ Hybridization Analysis of Philadelphia Chromosome-Negative Chronic Myeloid Leukemia with the bcr/abl Fusion Gene
    Fumihiko Monma
    Kazuhiro Nishii
    Shunji Yamamori
    Noboru Hosokai
    Takahiro Nakazaki
    Felipe Lorenzo V
    Eiji Usui
    Miho Sakakura
    Hiroyuki Miyashita
    Atsushi Fujieda
    Kohshi Ohishi
    Naoyuki Katayama
    Hiroshi Shiku
    International Journal of Hematology, 2004, 80 : 155 - 158
  • [29] Trisomy 13 in a Philadelphia negative chromosome and BCR-ABL negative myeloproliferative disorder
    Cabrol, C
    Samii, K
    Scherrer, A
    Darbellay, R
    Beris, P
    CANCER GENETICS AND CYTOGENETICS, 1999, 111 (02) : 184 - 185
  • [30] Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia
    Carella, Angelo Michele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (03) : 249 - 251
12345